Browsing by Author "Hadziyannis, S."
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
Item ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS (R)), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone(Wiley, 2004-10) Piratvisuth, T.; Marcellin, P.; Lau, G.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Lu, Z.M.; Germanidis, G.; Yurdaydın, C.; Diago, M.; Lai, M.Y.; Button, P.; Why, R.D.; Pluck, N.; Gürel, S.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.Bu çalışma, 29 Ekim- 02 Kasım 2004 tarihleri arasında Boston[Amerika Birleşik Devletleri]’nde düzenlenen 55. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)’da bildiri olarak sunulmuştur.Item First detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B: Data from a multicenter, randomized, partially double-blind study of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine alone(Wiley, 2004-10) Bonino, F.; Lau, G.; Macellin, P.; Hadziyannis, S.; Kitis, G.; Jin, R.; Yao, G.B.; Piratvisuth, T.; Germanidis, G.; Yurdaydın, Cihan; Diago, M.; Lai, M.; McCloud, P.; Brunetto, M.R.; Farci, P.; Gürel, Selim; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Bilim Dalı.Item A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.(Wiley, 2003-10) Marcellin, P.; Lau, G.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Lu, Z.; Piratvisuth, T.; Germanidis, G.; Yurdaydın, C.; Diago, M.; Lai, M.; Button, P.; Pluck, N.; Gürel, S.; Uludağ Üniversitesi/Tıp Fakültesi.; AAH-5364-2019; ABI-3764-2020Item Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone(Wiley, 2004-10) Germanidis, G.; Marcellin, P.; Lau, G.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Yao, G.B.; Piratvisuth, T.; Yurdaydın, C.; Diago, M.; Lai, M.Y.; Popescu, M.; Pluck, N.; Gürel, S.; Uludağ Üniversitesi/Tıp Fakültesi.